Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioridazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioridazine SCHEMBL9566 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL380206 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL29384252 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL2577719 | 1.00 | PIM1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL29387384 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL41430 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL8006297 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL30827481 | 0.99 | TDP1 (1.00) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL56533 | 0.98 | PIM1 (0.96) | PIM1CYP2D6DRD2CYP1A2HTR1A | |
| Thioridazine SCHEMBL28133267 | 0.94 | CYP2D6 (0.89) | PIM1CYP2D6DRD2CYP1A2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675814-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | Bläss, Markus (DE) | 2020-07-08 | — | — | EP | claimed |
| WO-2019043064-A1 | COMPOSITION FOR TOPICAL TREATMENT OF NON-MICROORGANISM-CAUSED INFLAMMATORY SKIN AND MUCOUS-MEMBRANE DISEASES | BLAESS MARKUS (DE) | 2019-03-07 | — | — | WO | claimed |
| US-12623047-B2 | Device, method, and app for facilitating sleep | NeuroLight, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12560572-B2 | Transistor-based biological assay system comprising mating receptacle plate and gate electrode plate | UNIVERSITA' DEGLI STUDI DI BARI ALDO MORO (IT) | 2026-02-24 | — | — | US | disclosed |
| US-20260048181-A1 | ANTIMICROBIAL POLYCARBONATE COATINGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-19 | — | — | US | disclosed |
| CN-120192314-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2025-06-24 | — | — | CN | disclosed |
| US-12319678-B2 | Thioridazine derivatives and their use for the treatment of cancer | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2025-06-03 | — | — | US | disclosed |
| US-20250170140-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING CARNITINE ACYLCARNITINE CARRIER INHIBITOR AND PEROXISOMAL BETA OXIDATION INHIBITOR | NEW CANCER CURE-BIO CO., LTD. (KR) | 2025-05-29 | — | — | US | disclosed |
| US-20250149336-A1 | PHOTORESIST COMPOSITION AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-05-08 | — | — | US | disclosed |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | CORNERSTONE PHARMACEUTICALS INC (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2024220043-A1 | A TRANSMISSION-BLOCKING COMPOSITION AGAINST PLASMODIUM VIVAX | MAHIDOL UNIVERSITY (TH) | 2024-10-24 | — | — | WO | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| CN-101198323-A | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH CORP (US) | 2008-06-11 | — | — | CN | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| CN-1726037-A | Treatment of headache with antipsychotics delivered by inhalation | ALEXZA MOLECULAR DELIVERY CORP (US) | 2006-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170140-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING CARNITINE ACYLCARNITINE CARRIER INHIBITOR AND PEROXISOMAL BETA OXIDATION INHIBITOR | ACOX1, CPT2, CPT1A | DRD2 4437/4885DRD3 4567/4885HTR2A 4482/4885 |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | PDK4, PDK2, PDK1 | DRD2 4494/4885DRD3 4744/4885HTR2A 3541/4885 |
| US-20260048181-A1 | ANTIMICROBIAL POLYCARBONATE COATINGS | TET2, TET3, DEPTOR | DRD2 31/4885DRD3 37/4885HTR2A 2466/4885 |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | DRD2 298/4885DRD3 296/4885HTR2A 146/4885 |
| US-12319678-B2 | Thioridazine derivatives and their use for the treatment of cancer | MLLT3, KMT2A, MLLT1 | DRD2 676/4885DRD3 661/4885HTR2A 1122/4885 |
| US-12623047-B2 | Device, method, and app for facilitating sleep | PER2, HCRTR2, NOTCH2 | DRD2 219/4885DRD3 530/4885HTR2A 113/4885 |
| US-12560572-B2 | Transistor-based biological assay system comprising mating receptacle plate and gate electrode plate | FSHR, GNRHR, KISS1R | DRD2 3350/4885DRD3 4220/4885HTR2A 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.